# Study to Evaluate the Safety, Efficacy of Tegoprazan for the Prevention of PUD in Patients on Treatment With NSAIDs

> **NCT04840550** · PHASE3 · UNKNOWN · sponsor: **HK inno.N Corporation** · enrollment: 390 (estimated)

## Conditions studied

- Preventive Peptic Ulcer

## Interventions

- **DRUG:** Lansoprazole 15 mg
- **DRUG:** Tegoprazan 25 mg

## Key facts

- **NCT ID:** NCT04840550
- **Lead sponsor:** HK inno.N Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-07
- **Primary completion:** 2024-06
- **Final completion:** 2024-07
- **Target enrollment:** 390 (ESTIMATED)
- **Last updated:** 2023-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04840550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04840550, "Study to Evaluate the Safety, Efficacy of Tegoprazan for the Prevention of PUD in Patients on Treatment With NSAIDs". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04840550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*